A phenome-wide study used data from the All of Us research program to connect second-line diabetes therapies with downstream health outcomes. The analysis, led by Salvatore, Zhang, Tang and colleagues, reportedly evaluates real-world trajectory effects beyond glycemic endpoints, potentially informing future comparative effectiveness work. The excerpt emphasizes that the dataset enabled broad outcome discovery after treatment exposure, reflecting a move toward “drug-to-trajectory” evidence generation in diabetes. The study’s design is positioned as a way to identify differential risk patterns that may not show up in narrower trials. For biotech and clinical stakeholders, the findings could influence how companies and investigators interpret second-line positioning and safety profiles, especially when multiple drug classes compete for similar patient populations.